Drug data last refreshed 3h ago · AI intelligence enriched 3h ago
ZOLOFT (sertraline hydrochloride) is a selective serotonin reuptake inhibitor (SSRI) approved for oral use as a concentrate formulation. It is indicated for depression, anxiety disorders, OCD, PTSD, and panic disorder by increasing serotonin availability in the central nervous system. This foundational psychiatric agent has been a standard-of-care treatment for over two decades.
Loss of exclusivity is imminent, signaling a transition from brand defense to generic containment and potential team consolidation or redeployment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Relative Bioavailability Study of Zoloft Oral Solution to Zoloft Tablets
Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects
A Study Comparing the Drug Exposure in Humans After Administration of a 50 mg Tablet of Sertraline Hydrochloride as Compared to a 50 mg Capsule of Sertraline Hydrochloride Under Fasted (Nonfed) Conditions
Drug Use Investigation of Jzoloft.
Special Investigation Of J Zoloft For Panic Disorder Patients
Worked on ZOLOFT at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZOLOFT offers limited growth opportunity but strong foundational experience in mature product management, generic defense, and payer negotiations. Roles focus on protecting market share against generics and optimizing formulary positioning rather than driving innovation or patient acquisition.